|
C1ORF9 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.39340000543586E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.94369999984012E-07 |
| Normal-vs-Stage2 |
1.06489999995851E-06 |
| Normal-vs-Stage3 |
4.11420000290263E-08 |
| Normal-vs-Stage4 |
9.50430000035141E-07 |
| Stage1-vs-Stage2 |
2.541600E-01 |
| Stage1-vs-Stage3 |
3.795800E-01 |
| Stage1-vs-Stage4 |
2.246400E-01 |
| Stage2-vs-Stage3 |
6.177400E-01 |
| Stage2-vs-Stage4 |
9.650400E-01 |
| Stage3-vs-Stage4 |
5.803400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.72470000503466E-08 |
| Normal-vs-AfricanAmerican |
2.371700E-02 |
| Normal-vs-Asian |
3.24229999959513E-07 |
| Caucasian-vs-AfricanAmerican |
2.034200E-01 |
| Caucasian-vs-Asian |
4.097800E-01 |
| AfricanAmerican-vs-Asian |
8.509900E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.27869953409277E-10 |
| Normal-vs-Female |
1.11760000032213E-07 |
| Male-vs-Female |
4.518300E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.55005999999958E-05 |
| Normal-vs-Age(41-60Yrs) |
3.74710040773607E-10 |
| Normal-vs-Age(61-80Yrs) |
6.31919999993791E-07 |
| Normal-vs-Age(81-100Yrs) |
3.920000E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.453800E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.218400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.928600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.015600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.360800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.362200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.153960E-01 |
| Classical-VS-Follicular |
3.336900E-03 |
| Classical-VS-Other |
1.494370E-01 |
| Classical-VS-Normal |
1.84370000000378E-06 |
| Tall-VS-Follicular |
5.276600E-01 |
| Tall-VS-Other |
3.320000E-01 |
| Tall-VS-Normal |
3.96430000004777E-06 |
| Follicular-VS-Other |
6.301200E-01 |
| Follicular-VS-Normal |
3.75489994652867E-09 |
| Other-VS-Normal |
2.536600E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.47229994862386E-09 |
| Normal-vs-N1 |
5.41150000032964E-07 |
| N0-vs-N1 |
7.722200E-01 |
|
|
